 Connection
Vernon Holers to Mutagenesis, Site-Directed
This is a "connection" page, showing publications Vernon Holers has written about Mutagenesis, Site-Directed.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.310 |
|
|
|
-
Hannan JP, Laskowski J, Thurman JM, Hageman GS, Holers VM. Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions. PLoS One. 2016; 11(11):e0166200.
Score: 0.127
-
Hannan JP, Young KA, Guthridge JM, Asokan R, Szakonyi G, Chen XS, Holers VM. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J Mol Biol. 2005 Feb 25; 346(3):845-58.
Score: 0.056
-
Ulgiati D, Holers VM. CR2/CD21 proximal promoter activity is critically dependent on a cell type-specific repressor. J Immunol. 2001 Dec 15; 167(12):6912-9.
Score: 0.045
-
Foley S, Li B, Dehoff M, Molina H, Holers VM. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol. 1993 Jun; 23(6):1381-4.
Score: 0.025
-
Shaw CD, Storek MJ, Young KA, Kovacs JM, Thurman JM, Holers VM, Hannan JP. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking. J Mol Biol. 2010 Dec 10; 404(4):697-710.
Score: 0.021
-
Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J Virol. 2008 Nov; 82(22):11217-27.
Score: 0.018
-
Young KA, Chen XS, Holers VM, Hannan JP. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21). J Biol Chem. 2007 Dec 14; 282(50):36614-25.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|